Bevacizumab-associated gastrointestinal perforation
- PMID: 19482241
- DOI: 10.1016/S1470-2045(09)70142-1
Bevacizumab-associated gastrointestinal perforation
Comment on
-
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.Lancet Oncol. 2009 Jun;10(6):559-68. doi: 10.1016/S1470-2045(09)70112-3. Lancet Oncol. 2009. PMID: 19482548
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources